- TREATMENT OF CD151 RELATED DISORDERS
-
The present invention relates to a method of treating a condition in a human related to CD151 the method comprising administering a therapeutically effective amount of a compound of Formula (I):
- -
-
Paragraph 0397-0398
(2022/02/09)
-
- METHOD OF TREATMENT OF CYTOMEGALOVIRUS
-
The present invention relates to a method of prophylaxis or treatment of Cytomegalovirus infection in a subject the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):
- -
-
Paragraph 0390-0391
(2022/02/09)
-
- METHODS OF PROPHYLAXIS AND TREATMENT OF CORONA VIRUS
-
The present invention relates to a method of prophylaxis or treatment of Corona virus infection in a subject the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):
- -
-
Paragraph 0399-0400
(2022/02/09)
-
- COMPOUNDS
-
The present invention relates to compounds of formula (I) that have the ability to inhibit CD151.
- -
-
Paragraph 0393; 0394
(2022/02/09)
-
- TREATMENT OF VETERINARY CONDITIONS ASSOCIATED WITH CD151
-
The present invention relates to a method of treating a condition related to CD151 in a non-human animal, the method comprising administering a therapeutically effective amount of a compound of Formula (I): Formula (I)
- -
-
Paragraph 0394
(2022/02/09)
-
- PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE
-
The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[l,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.
- -
-
-
- MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR
-
Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.
- -
-
Page/Page column 167; 168
(2018/06/30)
-
- Precision polyethylene: Changes in morphology as a function of alkyl branch size
-
Metathesis polycondensation chemistry has been employed to control the crystalline morphology of a series of 11 precision-branched polyethylene structures, the branch being placed on each 21st carbon and ranging in size from a methyl group to an adamantyl group. The crystalline unit cell is shifted from orthorhombic to triclinic, depending upon the nature of the precision branch. Further, the branch can be positioned either in the crystalline phase or in the amorphous phase of polyethylene, a morphology change dictated by the size of the precision branch. This level of morphology control is accomplished using step polymerization chemistry to produce polyethylene rather than conventional chain polymerization techniques. Doing so requires the synthesis of a series of unique symmetrical diene monomers incorporating the branch in question, followed by ADMET polymerization and hydrogenation to yield the precision-branched polyethylene under study. Exhaustive structure characterization of all reaction intermediates as well as the precision polymers themselves is presented. A clear change in morphology was observed for such polymers, where small branches (methyl and ethyl) are included in the unit cell, while branches equal to or greater in mass than propyl are excluded from the crystal. When the branch is excluded from the unit cell, all such polyethylene polymers possess essentially the same melting temperature, regardless of the size of the branch, even for the adamantyl branch.
- Rojas, Giovanni,Inci, Bora,Wei, Yuying,Wagener, Kenneth B.
-
supporting information; experimental part
p. 17376 - 17386
(2010/03/23)
-
- Gas-Phase Thermolysis of Pyrazolines, 3. - Electronic Structure and Gas-Phase Pyrolysis of 4-Substituted 3,5,5-Trialkyl-3,5-dihydro-4H-1,2,3-triazoles Studied by Photoelectron Spectroscopy and Semiempirical Calculations
-
The PE spectra of the 3,5-dihydro-4H-1,2,3-triazoles 1-3 have been recorded.The ionization potentials have been assigned to molecular orbitals on the basis of MNDO, AM1, and PM3 calculations.The most important occupied MOs are characterized as ?NNN, ?C=X (X = O, NCH3, CH2), nN-3, n+NN, n-NN and nX.The gas-phase thermolyses of 1-3 have been studied by PE-controlled real-time gas analysis.After extrusion of molecular nitrogen, the remaining reactive species cyclize to three-membered rings.At higher temperatures and in flash vacuum pyrolysis, subsequent reactions lead to smaller acyclic compounds. - Key Words: Electronic structure / Photoelectron spectroscopy / Gas-phase thermolysis / Pyrolysis / 4H-1,2,3-Triazoles, 3,5-dihydro- / Semiempirical MO calculations
- Kindermann, Markus Karl,Kowski, Klaus,Rademacher, Paul,Quast, Helmut
-
p. 2683 - 2690
(2007/10/02)
-
- α-ALKYLTHIO-NITRILES VIA CYANATION OF THIO-ACETALS AND KETALS
-
The reaction of thio-acetals or ketals with cyanotrimethylsilane in the presence of SnCl4 affords α-alkylthio-nitriles, which can be converted into a variety of other functional groups.
- Reetz, M. T.,Mueller-Starke, H.
-
p. 3301 - 3304
(2007/10/02)
-